Sandbox sss: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{meningitis}}
{{meningitis}}


====Streptococcus pneumoniae====
====Streptococcus pneumoniae====
{|
{|
|-
|-
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:20em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Penicillin MIC ≤0.06 μg/mL}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Penicillin]] MIC ≤0.06 μg/mL}}''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]<BR>Low: 600,000–1.2 million units/day IM <BR>High:≥ 20 million units IV q24h(=12 gm)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM <font color="#777777">; </font>High:≥ 20 million units IV q24h(=12 gm)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 24: Line 22:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]<BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''
|-
|-
|}
|}
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Penicillin MIC ≥0.12 μg/mL}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Penicillin]] MIC ≥0.12 μg/mL}}
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Cefotaxime or Ceftriaxone MIC† <1.0 μg/mL}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Cefotaxime]] or [[Ceftriaxone]] MIC† <1.0 μg/mL}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 43: Line 41:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]<BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 53: Line 51:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Cefotaxime or Ceftriaxone MIC† >1.0 μg/mL}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Cefotaxime]] or [[Ceftriaxone]] MIC† >1.0 μg/mL}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 61: Line 59:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''AND''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''AND''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h''''' <BR>''OR''<BR> ▸ '''''[[Ceftriaxone]]<BR>        1 gm IV qd <BR>''OR''<BR>      2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h''''' <BR>''OR''<BR> ▸ '''''[[Ceftriaxone]] 1 gm IV qd''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 79: Line 77:
|-
|-
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:20em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Neisseria meningitidis}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Neisseria meningitidis}}''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Penicillin MIC <0.1 μg/mL}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Penicillin]] MIC <0.1 μg/mL}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]<BR>Low: 600,000–1.2 million units/day IM <BR>High:≥ 20 million units IV q24h(=12 gm)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM <font color="#777777">;</font>High:≥ 20 million units IV q24h(=12 gm)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''  
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]<BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 107: Line 104:
|}
|}
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Neisseria meningitidis}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Neisseria meningitidis}}''
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Penicillin MIC ≥0.1 μg/mL}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|[[Penicillin]] MIC ≥0.1 μg/mL}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
Line 118: Line 115:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] <BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 144: Line 141:
|-
|-
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:20em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Listeria Monocytogenes}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Listeria Monocytogenes}}''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''  
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 gm)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]]<BR>Low: 600,000–1.2 million units/day IM <BR>High:≥ 20 million units IV q24h(=12 gm)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5–20 mg/kg/day q6-12h '''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5–20 mg/kg/day q6-12h '''''
|-
|-
|}
|}
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:20em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Streptococcus agalactiae}}''
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Streptococcus agalactiae}}''
|-
|-
Line 173: Line 167:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 gm)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Penicillin G]] <BR>Low: 600,000–1.2 million units/day IM <BR>High:≥ 20 million units IV q24h(=12 gm)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 182: Line 175:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] <BR> 1 gm IV qd <BR>''OR''<BR> 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h'''''
|-
|-
|}
|}
|}
|}


====Haemophilus influenzae====
====Haemophilus influenzae====
Line 205: Line 194:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen (Adult)''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen (Adult)''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen (Pediatric)''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen (Adult)''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen (Adult)''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]]'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Fluoroquinolone]]'''''
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen (Pediatric)''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]]'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 gm q8h–2 gm IV q6h'''''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]]'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 266: Line 227:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol,]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Chloramphenicol]] 0.25–1 gm po IV q6h to max. of 4 gm/day'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 gm q8h–2 gm IV q6h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 297: Line 258:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 310: Line 271:
{|
{|
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Staphylococcus aureus}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Staphylococcus aureus}}
|-
|-
Line 317: Line 278:
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]] 1–2 gm IV/IM q4h
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Nafcillin]]'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Oxacillin]] 1–2 gm IV/IM q4h
 
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Oxacillin]]'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]]'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[linezolid]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[linezolid]] 600 mg IV/PO q12h
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Daptomycin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Daptomycin]]'''''
|-
|-
|}
|}
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Staphylococcus aureus}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Staphylococcus aureus}}
|-
|-
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Meticillin resistant}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Meticillin resistant}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Trimethoprim-sulfamethoxazole]] 5–20 mg/kg/day q6-12h
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[linezolid]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[linezolid]] 600 mg IV/PO q12h
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Daptomycin]]'''''<BR><BR><BR>
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Daptomycin]]'''''<BR><BR><BR>
|-
|-
Line 376: Line 323:


====Staphylococcus epidermidis and Acinetobacter baumannii====
====Staphylococcus epidermidis and Acinetobacter baumannii====


{|
{|
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Staphylococcus epidermidis}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Staphylococcus epidermidis}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Vancomycin]] give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]]'''''<BR><BR><BR>
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Linezolid]] 600 mg IV/PO q12h<BR><BR><BR>
|-
|-
|}
|}
{|
{|
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Acinetobacter baumannii}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Acinetobacter baumannii}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
Line 408: Line 353:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Polymyxin B]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Polymyxin B]] 15,000–25,000 units/kg/day q12h
|-
|-
|}
|}
Line 414: Line 359:


====Enterobacteriaceae and Pseudomonas aeruginosa====
====Enterobacteriaceae and Pseudomonas aeruginosa====


{|
{|
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterobacteriaceae}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Enterobacteriaceae}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime ]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefotaxime]] 1 gm q8–12h to 2 gm IV q4h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]] 1 gm IV qd ''OR'' 2 g IV q12h(for Purulent meningitis  also IM in 1% lidocaine)'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftriaxone]]'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 gm q8h–2 gm IV q6h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
Line 447: Line 387:
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 0.25–0.5 gm po q6h.150–200 mg/kg/day IV'''''
|-
|-
|}
|}
{|
{|
| valign=top |
| valign=top |
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:35em" cellpadding="0" cellspacing="0";
{| style="margin: 0 0 0em 0em; border: 1px solid #696969; float: left; width:40em" cellpadding="0" cellspacing="0";
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pseudomonas aeruginosa}}
! style="padding: 0 5px; font-size: 100%; background: #F8F8FF" align=center | ''{{fontcolor|#6C7B8B|Pseudomonas aeruginosa}}
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Preferred Regimen''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime ]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ceftazidime ]] 1–2 gm IV/IM q8–12h'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]]'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Cefepime]] 1–2 gm IV q12h'''''
|-
|-
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
! style="padding: 0 5px; font-size: 80%; background: #F5F5F5" align=left | ''Alternative Regimen''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]] 1 gm q8h–2 gm IV q6h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aztreonam]]'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
 
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]] 2 gm IV q8h'''''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Meropenem]]'''''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ''OR''
|-
|-
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]]'''''<BR><BR><BR><BR><BR>
| style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 500-750 mg po bid'''''<BR><BR><BR><BR><BR>
|-
|-
|}
|}
|}
|}

Revision as of 20:06, 16 January 2014

Meningitis Main Page

Patient Information

Overview

Causes

Classification

Viral Meningitis
Bacterial Meningitis
Fungal Meningitis

Differential Diagnosis

Diagnosis

Treatment

Streptococcus pneumoniae

Penicillin MIC ≤0.06 μg/mL
Preferred Regimen
Penicillin G Low: 600,000–1.2 million units/day IM ; High:≥ 20 million units IV q24h(=12 gm)
OR
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
Alternative Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Chloramphenicol 0.25–1 gm po IV q6h to max. of 4 gm/day
Penicillin MIC ≥0.12 μg/mL
Cefotaxime or Ceftriaxone MIC† <1.0 μg/mL
Preferred Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Cefepime 1–2 gm IV q12h
OR
Meropenem 2 gm IV q8h
Cefotaxime or Ceftriaxone MIC† >1.0 μg/mL
Preferred Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
AND
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qdOR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
AND
Moxifloxacin 400 mg po IV q24h

Neisseria meningitidis

Neisseria meningitidis
Penicillin MIC <0.1 μg/mL
Preferred Regimen
Penicillin G Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 gm)
OR
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
Alternative Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Chloramphenicol 0.25–1 gm po IV q6h to max. of 4 gm/day


Neisseria meningitidis
Penicillin MIC ≥0.1 μg/mL
Preferred Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Cefepime 1–2 gm IV q12h
OR
Chloramphenicol 0.25–1 gm po IV q6h to max. of 4 gm/day
OR
Fluoroquinolone
OR
Meropenem 2 gm IV q8h

Listeria Monocytogenes and Streptococcus agalactiae

Listeria Monocytogenes
Preferred Regimen
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
OR
Penicillin G Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 gm)
Alternative Regimen
Trimethoprim-sulfamethoxazole 5–20 mg/kg/day q6-12h
Streptococcus agalactiae
Preferred Regimen
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
OR
Penicillin G Low: 600,000–1.2 million units/day IM ;High:≥ 20 million units IV q24h(=12 gm)
Alternative Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h

Haemophilus influenzae

Haemophilus influenzae
β-lactamase negative
Preferred Regimen (Adult)
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
Alternative Regimen (Adult)
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
OR
Cefepime 1–2 gm IV q12h
OR
Chloramphenicol 0.25–1 gm po IV q6h to max. of 4 gm/day
OR
Aztreonam 1 gm q8h–2 gm IV q6h
OR
Fluoroquinolone
Haemophilus influenzae
β-lactamase positive
Preferred Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Cefepime 1–2 gm IV q12h
OR
Chloramphenicol 0.25–1 gm po IV q6h to max. of 4 gm/day
OR
Aztreonam 1 gm q8h–2 gm IV q6h
OR
Fluoroquinolone
Haemophilus influenzae
β-lactamase negative, ampicillin resistant
Preferred Regimen
Meropenem 2 gm IV q8h
Alternative Regimen
Fluoroquinolone

Staphylococcus aureus

Staphylococcus aureus
Meticillin sensitive
Preferred Regimen
Nafcillin 1–2 gm IV/IM q4h
OR
Oxacillin 1–2 gm IV/IM q4h
Alternative Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
OR
linezolid 600 mg IV/PO q12h
OR
Daptomycin
Staphylococcus aureus
Meticillin resistant
Preferred Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
Alternative Regimen
Trimethoprim-sulfamethoxazole 5–20 mg/kg/day q6-12h
OR
linezolid 600 mg IV/PO q12h
OR
Daptomycin


Staphylococcus epidermidis and Acinetobacter baumannii

Staphylococcus epidermidis
Preferred Regimen
Vancomycin give loading dose of 25-30 mg/kg IV then 15-20 mg/kg IV q8-12h
Alternative Regimen
Linezolid 600 mg IV/PO q12h


Acinetobacter baumannii
Preferred Regimen
Meropenem 2 gm IV q8h
Alternative Regimen
Colistin
OR
Polymyxin B 15,000–25,000 units/kg/day q12h

Enterobacteriaceae and Pseudomonas aeruginosa

Enterobacteriaceae
Preferred Regimen
Cefotaxime 1 gm q8–12h to 2 gm IV q4h
OR
Ceftriaxone 1 gm IV qd OR 2 g IV q12h(for Purulent meningitis also IM in 1% lidocaine)
Alternative Regimen
Aztreonam 1 gm q8h–2 gm IV q6h
OR
Fluoroquinolone
OR
Trimethoprim-sulfamethoxazole
OR
Meropenem 2 gm IV q8h
OR
Ampicillin 0.25–0.5 gm po q6h.150–200 mg/kg/day IV
Pseudomonas aeruginosa
Preferred Regimen
Ceftazidime 1–2 gm IV/IM q8–12h
OR
Cefepime 1–2 gm IV q12h
Alternative Regimen
Aztreonam 1 gm q8h–2 gm IV q6h
OR
Meropenem 2 gm IV q8h
OR
Ciprofloxacin 500-750 mg po bid